Novo Nordisk loses ground as Eli Lilly's Zepbound reshapes weight loss drug race
Novo Nordisk loses ground as Eli Lilly's Zepbound reshapes weight loss drug race
Novo Nordisk loses ground as Eli Lilly's Zepbound reshapes weight loss drug race
Novo Nordisk is facing growing competition in the weight loss drug market. The company's latest treatment, CagriSema, failed to outperform Eli Lilly's Zepbound in a key trial. Meanwhile, its market share in the GLP-1 sector has dropped steadily over the past three years.
Between 2023 and 2025, Novo Nordisk's share of the GLP-1 market fell from around 55% to 45% globally. In the same period, Eli Lilly's share jumped from 35% to 50%, boosted by the late-2023 launch of Zepbound and stronger supply growth. This shift has put pressure on Novo Nordisk's dominance in a market expected to expand significantly over the next decade.
The company's revenue is now projected to decline in 2026 compared to the previous year. Its shares have also underperformed relative to the broader stock market in recent years. Despite these challenges, Novo Nordisk still holds a strong position in diabetes treatments and is working to broaden its product range.
Novo Nordisk's pipeline includes several GLP-1 candidates nearing approval. The firm also has the financial strength and expertise to pursue licensing deals and acquisitions. However, its latest weight loss drug, CagriSema, did not match the effectiveness of Eli Lilly's Zepbound in a phase 3 study, highlighting the intensifying competition.
Novo Nordisk remains a major player in diabetes and GLP-1 drugs, but its grip on the market is weakening. With new treatments in development and resources for expansion, the company is looking to regain momentum. The coming years will test its ability to compete against Eli Lilly's growing influence.